<DOC>
	<DOCNO>NCT00393497</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness bevacizumab woman lymphedema result previous treatment breast cancer .</brief_summary>
	<brief_title>A Pilot Study VEGF Inhibition Patients With Lymphedema Following Breast Cancer Treatment</brief_title>
	<detailed_description>The primary objective study : â€¢ To assess degree improvement arm edema measure change arm volume patient ipsilateral lymphedema The secondary objective study : - To assess degree improvement arm edema measure change arm interstitial fluid pressure ( IFP ) - To assess degree improvement arm edema measure change extracellular fluid ( ECF ) volume base bioelectrical impedance analysis ( BIA ) lymphometer - To assess safety tolerability VEGF inhibition patient population - To assess clinical benefit patient ipsilateral lymphedema treat vascular endothelial growth factor ( VEGF ) inhibition evaluate patient response quality life questionnaire ( FACT-B+4 lymphedema question ) - To determine impact VEGF inhibition circulate VEGF level patient lymphedema</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Have unilateral lymphedema ipsilateral arm attribute prior surgical treatment radiation therapy breast cancer severe enough warrant therapy opinion subject treat physician . 2 . All subject must great 3 cm total difference arm circumference affect unaffected arm measure five defined point : hand distal thumb wrist narrow point arm 30 cm proximal tip middle finger arm 40 cm proximal tip middle finger arm 50 cm proximal tip middle finger ( possible axilla reach . ) 3 . Be least 18 year age 4 . Have adequate organ function specify : AST ALT less equal 2.0 time ULN Total bilirubin less equal 1.5 mg/dL Serum creatinine less equal 1.5 mg/dL Urine protein : creatinine ratio &lt; 1.0* LVEF &gt; institutional limit normal MUGA ECHO PT INR &lt; 1.5 ; PTT &lt; 1.5 x normal Absolute neutrophil count great equal 1000/mm3 Platelets great equal 100,000/mm3 5 . Agree use effective contraceptive method course study subject childproducing potential 6 . Have ECOG performance status 0 1 1 . Subjects must pregnant , lactate , refuse use appropriate birth control 2 . Subjects must active infection require parenteral oral antibiotic 3 . Subjects must clinically significant cardiovascular cerebrovascular disease , include : Any history : Cerebrovascular disease include TIA , stroke subarachnoid hemorrhage Ischemic bowel Hypertensive crisis hypertensive encephalopathy Within last 12 month Myocardial infarction Unstable angina New York Heart Association ( NYHA ) grade II great congestive heart failure Grade II great peripheral vascular disease DVT PE Active study entry Uncontrolled hypertension define SBP &gt; 150 DBP &gt; 100 Uncontrolled clinically significant arrhythmia . 4 . Subjects may locally recurrent metastatic disease 5 . Subjects may require concurrent therapeutic anticoagulation . ( NOTE : Prophylactic dos coumadin maintain patency vascular access device allow ) . In addition , subject bleed diathesis exclude . 6 . Subjects may major surgery within 4 week start protocol therapy ( NOTE : Placement vascular access device consider major surgery ) 7 . Subjects may receive radiation therapy , chemotherapy trastuzumab within past 6 week ( NOTE : Concurrent adjuvant hormonal therapy allow . ) 8 . Subjects may alter physical therapy regimen lymphedema within past month 9 . Subjects may indwell venous device ipsilateral arm 10 . Subjects may bilateral lymphedema 11 . Subjects may nonhealing wound , ulcer bone fracture . 12 . Subjects may know hypersensitivity component Bevacizumab</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>lymphedema</keyword>
</DOC>